Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
domingo, octubre 25
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Bicara Therapeutics Inc
BCAX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$17.07
-0.54
-3.07%
Últ. Act.: Oct 23, 4:00 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Bicara Therapeutics Financials
Bicara Therapeutics (BCAX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings
Avi Kapoor
PRO
Bicara Therapeutics Q2 EPS $(0.82) Beats $(0.84) Estimate
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.84) by 2.38 percent. This is a 64 percent decrease over losses of $(0.50) per share from
Benzinga Newsdesk
PRO
Bicara Therapeutics Q1 EPS $(0.93) Misses $(0.68) Estimate
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.68) by 36.76 percent. This is a 36.76 percent decrease over losses of $(0.68) per share
Benzinga Newsdesk
Earnings Scheduled For May 11, 2026
Benzinga Insights
PRO
Bicara Therapeutics Q4 EPS $(0.68), Inline
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 74.36 percent decrease over losses of $(0.39) per share from the same period last year.
Benzinga Newsdesk
Earnings Scheduled For March 30, 2026
Benzinga Insights
